SpyGlass Pharma SGP
$30.43 −$0.35 (-1.14%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $30.43 0.00%
Open$30.12
Prev close$30.78
Day range$29.07 – $31.73
Volume108.9K
Market cap$1.02B
P/E (TTM)–
Dividend yield–
SGP Stock News
Headlines matching SpyGlass Pharma or the SGP ticker, most recent first.
- Dentsu Ventures SGP Fund invests in Facilo, a company supporting digital transformation in the real estate industry.
- Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR)
- Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39
- Soracom: Commercial availability of the profile management platform "SORACOM Connectivity Hypervisor" has begun, enabling flexible operation of SGP.32‑compatible IoT SIMs.
- Soracom: Jointly developed an IoT SIM card compatible with the next-generation eSIM standard "SGP.32," with phased rollout beginning on July 7.
- Jefferies Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Maintains Target Price $62
- Citi Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $42
- Analysts Offer Insights on NA Companies: SpyGlass Pharma (SGP) and Ottobock SE & Co. KGaA (OBCKF)
- Leerink Partners Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $42
- Jefferies Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $62
- Analysts Offer Insights on NA Companies: BitGo Holdings, Inc. Class A (BTGO) and SpyGlass Pharma (Nasdaq: SGP)
- H.C. Wainwright Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $37
- Citi Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Maintains Target Price $42
- STMicroelectronics Simplifies IoT Deployment With SoftSIM, SGP.32 In-factory Provisioning, and Zephyr Support for ST87M01
- Citi Maintains SpyGlass Pharma(SGP.US) With Buy Rating, Raises Target Price to $45 Positive
No comments yet — be the first to weigh in on SGP.
Sign in to join the discussion.